Compositions Comprising Nebivolol

Abstract

Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.

1 - 36 . (canceled) 
     
     
         37 . A composition comprising nebivolol or a pharmaceutically acceptable salt thereof, and an angiotensin II receptor antagonist (ARB) selected from the group consisting of olmesartan, valsartan, losartan, and combinations thereof, and pharmaceutically acceptable salts thereof. 
     
     
         38 . The composition of  claim 37 , wherein the ARB is selected from the group consisting of losartan, valsartan, and combinations thereof, and pharmaceutically acceptable salts thereof. 
     
     
         39 . The composition of  claim 37 , wherein the ARB is losartan or a pharmaceutically acceptable salt thereof. 
     
     
         40 . A method of treating or preventing hypertension in a patient in need thereof, comprising administering to said patient an effective amount of nebivolol or a pharmaceutically acceptable salt thereof, and an angiotensin II receptor antagonist (ARB) selected from the group consisting of olmesartan, valsartan, losartan, and combinations thereof, and pharmaceutically acceptable salts thereof. 
     
     
         41 . The method of  claim 40 , wherein the ARB is selected from the group consisting of losartan, valsartan, and combinations thereof, and pharmaceutically acceptable salts thereof. 
     
     
         42 . The method of  claim 40 , wherein the ARB is losartan or a pharmaceutically acceptable salt thereof. 
     
     
         43 . A method of treating or preventing cardiovascular disease in a patient in need thereof, comprising administering to said patient an effective amount of nebivolol or a pharmaceutically acceptable salt thereof, and an angiotensin II receptor antagonist (ARB) selected from the group consisting of olmesartan, valsartan, losartan, and combinations thereof, and pharmaceutically acceptable salts thereof. 
     
     
         44 . The method of  claim 43 , wherein the ARB is selected from the group consisting of losartan, valsartan, and combinations thereof, and pharmaceutically acceptable salts thereof. 
     
     
         45 . The method of  claim 43 , wherein the ARB is losartan or a pharmaceutically acceptable salt thereof.